Immunogenicity of Biosimilar Therapeutics in Drug Development (Q167968): Difference between revisions
From geokb
(Changed label, description and/or aliases in en, and other parts: modified description with assistance from Llama 3.1) |
(Changed an Item: moved OpenAlex ID to its dedicated external ID datatype for consistency) |
||
| Property / same as | |||
| Property / same as: https://openalex.org/T12255 / rank | |||
| Property / OpenAlex ID | |||
| Property / OpenAlex ID: T12255 / rank | |||
Normal rank | |||
Revision as of 12:25, 8 September 2024
Investigating the safety and effectiveness of biosimilar drugs, including testing methods and potential side effects.
- Biosimilars
- Immunogenicity
- Bioanalytical Methods
- Therapeutic Proteins
- Dried Blood Spots
- Erythropoietin Antibodies
- Monoclonal Antibodies
- Regulatory Guidelines
- Biopharmaceuticals
- Clinical Outcomes
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Immunogenicity of Biosimilar Therapeutics in Drug Development |
Investigating the safety and effectiveness of biosimilar drugs, including testing methods and potential side effects. |
|
